ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enveric Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.39+0.01 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $5.54M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.72 (−84.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.69
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.73M
- EPS, diluted
- -$18.77
- Book value per share
- $2.03
- Diluted shares
- 4M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$8.73M
Net income
-$8.73M
EPS, diluted
-$18.77
Free cash flow
–
Reported periodTrailing twelve months